Abstract:Abstract Metastasis is the main cause of cancer-related death and prevention of metastatic relapse is, therefore, the most important goal of cancer therapy. Distant metastases harbour unique genomic characteristics not detectable in the corresponding primary tumor of the same patient and metastases located at different sites show a considerable intra-patient heterogeneity. Thus, the mere analysis of the resected primary tumor alone (current standard practise in oncology) or, if possible, even re-evaluation of tumor characteristics based on the biopsy of the most accessible metastasis may not reveal sufficient information for treatment decisions. This dilemma can be solved by a new diagnostic concept: Liquid biopsy, i.e., analysis of therapeutic targets and drug resistance-conferring gene mutations on circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) released into the peripheral blood from metastatic deposits. In addition, cell-free microRNAs in the peripheral blood of cancer patients may provide real-time insights into the biology of cancer, including the effects of therapeutic interventions. MicroRNA levels in plasma, serum, urine and other body fluids have been used to detect cancer, predict the prognosis and response to therapy. Here the current challenges and future perspectives of CTCs and circulating nucleic acids as biomarkers in clinical oncology will be discussed. Both CTCs and circulating nucleic acids are interesting complementary technologies that can be used in parallel in future trials assessing new drugs or drug combinations. We postulate that the liquid biopsy concept will contribute to a better understanding and prevention of metastatic relapse and progression in cancer patients. Citation Format: Klaus Pantel. Circulating tumor cells versus circulating tumor cell products. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr ED06-03.

Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance

Never Travel Alone: The Crosstalk of Circulating Tumor Cells and the Blood Microenvironment

Circulating tumor cells: biology and clinical significance

Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?

Circulating Tumour Cell Clusters: Isolation, Biological Significance and Therapeutic Implications

Circulating Tumor Cells: Biological Features and Survival Mechanisms

Platelets and circulating (tumor) cells: partners in promoting metastatic cancer

Circulating Tumor Cells: From Basic to Translational Research

Circulating Tumor Cells (CTCs): A Unique Model of Cancer Metastases and Non-invasive Biomarkers of Therapeutic Response

Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications

Circulating and Disseminated Tumor Cells: Diagnostic Tools and Therapeutic Targets in Motion

Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance

Survival mechanisms of circulating tumor cells and their implications for cancer treatment

Red blood cell-tumour cell interactions promote tumour cell progression

Circulating Tumor Cells: How Far Have We Come with Mining These Seeds of Metastasis?

Mechanobiology and survival strategies of circulating tumor cells: a process towards the invasive and metastatic phenotype

The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance

Abstract ED06-03: Circulating tumor cells versus circulating tumor cell products

Better together: circulating tumor cell clustering in metastatic cancer

Circulating tumor cell clusters: Insights into tumour dissemination and metastasis

Molecular Characterization of Circulating Tumor Cells-from Bench to Bedside